tbuckley/cabot-search huggingface dataset:
AB0042 Identification of Sulfido-Conjugated Mediators That Promote Resolution of Infection and Organ Protection
Authors: J. Dalli, N. Chiang, C. Serhan
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> When inflammation is self-limited it is host protective and leads to the repair and regeneration of damaged tissues. Chronic conditions, such as inflammatory arthritis, are though to arise from a failure of the host response to engage resolution mechanisms. The pro-resolving mechanisms engaged by the host response to promote tissue regeneration remain of interest. <h3>Objectives</h3> In the present stud we aim to identify mediators produced during the resolution phase of acute inflammation, that promote the termination of the inflammatory response, tissue repair and regeneration. <h3>Methods</h3> We employed LC-MS-MS and RP-UV-HPLC based lipid mediator metabolololipodomics to investigate novel bioactive molecules in isolates from mouse and human tissues and cells. Bioactions for identification and characterization of the novel molecules were determined using planaria, mice and human primary leukocytes. <h3>Results</h3> Here we identified potent molecules present in infectious murine exudates, regenerating planaria, human milk as well as macrophages that stimulated tissue regeneration in planaria and are pro-resolving. Characterization of their physical properties and isotope tracking indicated that the bioactive structures contained sulfido-conjugated (SC) triene double bonds that proved to be 13-glutathionyl,14-hydroxy-docosahexaenoic acid (SCI) and 13-cysteinylglycinyl, 14-hydroxy-docosahexaenoic acid (SCII). These molecules rescued <i>E. coli</i> infection-mediated delay in tissue regeneration in planaria, improving regeneration intervals from ∼4.2 to ∼3.7 days. Administration of SC protected mice from second organ injury and promoted repair via limiting neutrophil infiltration, upregulating Ki67 and Roof plate-specific spondin 3 in lung tissues. At nanomolar potencies these conjugates also resolved <i>E. coli</i> infections by limiting neutrophil infiltration, stimulating bacteria phagocytosis and clearance as well as efferocytosis of apoptotic cells. <h3>Conclusions</h3> Together, these findings identify previously undescribed, conserved chemical signals and pathways in planaria, mice and human tissues that stimulate resolution of inflammation and promote the restoration of function. <h3>Acknowledgement</h3> This work was supported in part by the National Institutes of Health (Grant P01GM095467). <h3>Disclosure of Interest</h3> None declared
FACTORES DE RIESGO DE HEMORRAGIA DIGESTIVA DE ORIGEN OSCURO EN PACIENTES CON CONSUMO CRÓNICO DE AINES: UN ESTUDIO DE CASOS Y CONTROLES
Authors: E Pérez-Cuadrado Robles, A López-Higueras, JL Rodrigo Agudo, B Martinez Andrés, JF Sánchez Melgarejo, H Hallal, E Pérez-Cuadrado Martinez
Journal: Endoscopy (2015)

Introducción: La enteropatía por AINE de intestino delgado es una entidad de creciente importancia que cada vez se diagnostica con más frecuencia en pacientes con hemorragia digestiva de origen oscuro (HDOO), sin conocerse su incidencia ni factores de riesgo.
Renal Metastasis From Primary Thyroid Cancer on 131I and MRI Imaging
Authors: Darshan R. Patel, Bhishak H. Kamat, Michael D. Farwell
Journal: Clinical Nuclear Medicine (2016)

A 66-year-old woman with a history of papillary thyroid cancer status after total thyroidectomy underwent 131I radioiodine ablation therapy 3 months after surgery. Posttherapy whole body planar imaging revealed focal intense 131I uptake in the posterior right abdomen. SPECT/CT of this region localized the uptake to the medial lower pole of the right kidney. Further evaluation with MRI demonstrated a correlative suspicious right renal mass. The patient underwent right partial nephrectomy with pathology demonstrating that the renal mass was of thyroidal origin (papillary subtype).
HIV Transmission During Condomless Sex With a Seropositive Partner With Suppressed Infection
Authors: Jason D. Goldman, Lisa M. Frenkel, James I. Mullins
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Multi-Site, Prospective Cross-Over Study of Intranasal Desmopressin and Oral Tranexamic Acid in Women with Menorrhagia and Abnormal Laboratory Hemostasis.
Authors: Peter A. Kouides, John A. Heit, Claire S. Philipp, Sid F. Stein, Andrea S. Lukes, Vanessa R. Byams, Nicole F. Dowling, Bruce L. Evatt, Connie R. Miller, Sally Owens, Nyasha Skerette, Roshni Kulkarni
Journal: Blood (2007)
Regulation of autoantibody activity by the IL-23–TH17 axis determines the onset of autoimmune disease
Authors: René Pfeifle, Tobias Rothe, Natacha Ipseiz, Hans U Scherer, Stephan Culemann, Ulrike Harre, Jochen A Ackermann, Martina Seefried, Arnd Kleyer, Stefan Uderhardt, Benjamin Haugg, Axel J Hueber, Patrick Daum, Gordon F Heidkamp, Changrong Ge, Sybille Böhm, Anja Lux, Wolfgang Schuh, Iryna Magorivska, Kutty S Nandakumar, Erik Lönnblom, Christoph Becker, Diana Dudziak, Manfred Wuhrer, Yoann Rombouts, Carolien A Koeleman, René Toes, Thomas H Winkler, Rikard Holmdahl, Martin Herrmann, Stephan Blüml, Falk Nimmerjahn, Georg Schett, Gerhard Krönke
Journal: Nature Immunology (2016)
Safety of Eltrombopag, an Oral Non-Peptide Platelet Growth Factor, in the Treatment of Thrombocytopenia: Results of Four Randomized, Placebo-Controlled Studies
Authors: James B. Bussel, John McHutchison, Drew Provan, A. Jagiello-Gruzfeld, Rezvan Rafi, Sophia Goodison
Journal: Blood (2007)
Oxidative stress-induced DNA-damage in the Barretts carcinogenesis
Authors: Diana Walluscheck, Vanessa Neumann, Christine Fathke, Abbas Agaimy, Angela Poehlmann, Thomas Guenther, Peter Wuensch, Hans-Ulrich Schulz, Michael Vieth, Bernd Stolte, Wael El-Rifai, Albert Roessner, Regine Schneider-Stock
Journal: Cancer Research (2008)

3138  Aims: It is widely accepted that oxidative stress plays a significant role in the pathogenesis of Barrett’s esophagus. In order to investigate if oxidative stress induces DNA-damage or not, we performed in vivo and in vitro studies. Methods: As a sensitive marker for oxidative damage, we investigated immunohistochemically the 8-hydroxy-deoxyguanosine (8-OHdG) level in 50 Barrett’s carcinomas (BCa) and 52 precursor lesions [21 Barrett mucosas (BM), 20 low grade dysplasia (LGD), and 11 high grade dysplasia (HGD)]. In parallel, the base excision repair proteins, OGG1 and MYH, were analyzed for protein expression by immunohistochemistry and for mutations (hot spots: Y165C and G382D) using a pyrosequencer. In addition, three Barrett’s adenocarcinoma cell lines (SEG1, TE7, and BIC1) were treated with 250µM H2O2 for 6, 24, and 48h, and induction of oxidative DNA-damage was measured by 8-OHdG staining and COMET assay. γH2A.X expression and cytochrome c release were determined by Western Blotting. Effects on apoptosis and cell cycle distribution were determined by Annexin V assay, caspase 3, 8, and 9 cleavage and FACS analysis. Results: The 8-OHdG score differed significantly between BM and BCa. There was one case with a hereditary heterozygous MYH mutation. H2O2 treatment induced severe DNA-damage as reflected by a dramatic increase in DNA double strand breaks within 15min posttreatment. Oxidative DNA-damage was accompanied by G2/M arrest and apoptosis induction dependent on the p53 status of the tumor cells. Conclusions:Increased DNA-damage during Barrett’s carcinogenesis is associated with a decrease in the antioxidant and repair capacities. Therefore, oxidative stress inducing DNA-damaging agents might have a therapeutic impact on Barrett’s adenocarcinomas.
CONCANAVALIN-A STIMULATED PERIPHERAL MONONUCLEAR BLOOD-CELLS (PBC) FROM PATIENTS WITH MINIMAL CHANGE GLOMERULOPATHY AFFECT GLOMERULAR POLYANION (GPA) INVITRO
Authors: Ww Bakker, [No Value] Beukof, Pj Hoedemaeker, Gk Vanderhem, Whj Vanluij
Journal: Kidney International (1982)
Analysis of the Cellular Components of the Graft and Clinical Characteristics of 159 Children with Lysosomal and Peroxisomal Disorders (LSD) Undergoing Unrelated Umbilical Cord Blood Transplantation at a Single Center.
Authors: Vinod K. Prasad, Adam Medizabal, Suhag H. Parikh, Paul Szabolcs, Timothy A. Driscoll, Kristin Page, Sonali Lakshminarayanan, June Allison, Susan Wood, Deborah Semmell, Maria L. Escolar, Paul L. Martin, Shelly Carter, Joanne Kurtzberg
Journal: Blood (2007)
Clinical Significance of Dose Reductions of Dasatanib and Nilotinib When Used As Frontline Therapy for Chronic Phase -Chronic Myeloid Leukemia (CML-CP) Does Not Affect Outcome,
Authors: Asifa Malik, Hagop M. Kantarjian, Alfonso Quintas-Cardama, Susan o'Brien, Srdan Verstovsek, Gautam Borthakur, Farhad Ravandi, Deborah A. Thomas, Elizabeth M Burton, Elias Jabbour, Jorge E. Cortes
Journal: Blood (2011)
Proteomic Signature of CD34+ Cells From Chronic Myeloid Leukemia Patients
Authors: Maria Rosaria Ricciardi, Valentina Salvestrini, Roberto Licchetta, Simone Mirabilii, Maria Teresa Petrucci, Lara Rossi, Matteo Allegretti, Simona Salati, Fausto Castagnetti, Gianantonio Rosti, Giuliana Alimena, Rossella Manfredini, Roberto M. Lemoli, Agostino Tafuri
Journal: Blood (2012)
Immunotherapy with LAK Cells and Anti-CD20 Monoclonal Antibodies for Follicular Lymphoma: Enhanced Antibody-Dependent Cell Cytotoxicity of LAK Cells in Association with GA101 Rather Than Rituximab
Authors: Carlos Panizo, Susana Inoges, Ascensión López Díaz de Cerio, Ricardo García Muñoz, Fernando Pastor, Carlos Grande García, Mayte Olave, Luis Palomera, Jose J. Rifon, Sara Barea, Ana Alfonso, Maurizio Bendandi
Journal: Blood (2012)
Patients with multimorbidity need longer GP consultations, says RCGP
Authors: Jacqui Wise
Journal: BMJ (2016)

Patients with multiple long term conditions should have longer GP consultations to provide more time to discuss the complexities of their conditions, a new report from the Royal College of General Practitioners (RCGP) recommends.

The report, Responding to the Needs of Patients with Multimorbidity: a Vision for General Practice ,1 says that patients with multiple long term conditions often have a worse experience of the health and social care system. This includes short consultations and care that is fragmented because of the disjointed approach of …
Dose-response analyses of uric acid and risk of type 2 diabetes in a Chinese occupational population: a cohort study and meta-analysis
Authors: Aimin Yang, Simin Liu, Ning Cheng, Hongquan Pu, Min Dai, Jiao Ding, Juansheng Li, Haiyan Li, Xiaobin Hu, Xiping Shen, Jie He, Tongzhang Zheng, Yana Bai
Journal: The Lancet Diabetes & Endocrinology (2016)
Infectious Complications After Unrelated Umbilical Cord Blood Transplantation (UCBT) in Adult Patients with Hematological Malignancies.
Authors: Xavier Cahu, Fanny Rialland, Cyrille Touzeau, Patrice Chevallier, Thierry Guillaume, Jacques Delaunay, Sameh Ayari, Viviane Dubruille, Steven Le Gouill, Beatrice Mahe, Thomas Gastinne, Nicolas Blin, Beatrice Saulquin, Jean-Luc Harousseau, Philippe Moreau, Francoise Mechinaud, Mohamad Mohty
Journal: Blood (2009)
An Anti-Apoptotic Molecule, Anamorsin, Is Essential for Erythropoiesis Through the Regulation of Cellular Labile Iron Pool
Authors: Akira Tanimura, Yuri Hamanaka, Natsuko Fujita, Yukiko Doi, Tomohiko Ishibashi, Takao Sudo, Keiko Matsui, Michiko Ichii, Norimitsu Saitoh, Yusuke Satoh, Sachiko Ezoe, Takafumi Yokota, Kenji Oritani, Hirohiko Shibayama, Yuzuru Kanakura
Journal: Blood (2012)
Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor Have Normal T Cell Responses to Vaccination but An Impaired IgM Humoral Response Associated with Loss of Discrete Memory B Cell Subsets,
Authors: Hugues de Lavallade, David Marin, Melanie Hart, Takuya Sekine, Ian Gabriel, Abdullah Alsuliman, Alexandra Bazeos, Ahmad Khoder, Kate Stringaris, Jamshid Khorashad, Nichola Cooper, Dragana Milojkovic, Letizia Foroni, Richard M Szydlo, Aristeidis Chaidos, Amr R Ibrahim, Marco Bua, John M Goldman, Jane F Apperley, William P Kelleher, Katayoun Rezvani
Journal: Blood (2011)
OP0136 Abatacept Treatment during 1 Year Period in Juvenile Idiopathic Arthritis Associated Uveitis without Previous Biologics Therapy
Authors: L. Galstian, E. Zholobova, O. Loskutova, M. Nikolaeva
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Biological DMARDs have an important role in the treatment of juvenile idiopathic arthritis (JIA) associated uveitis refractory to previous standard treatment. <h3>Objectives</h3> The aim of this prospective study was assessment of Abatacept (ABA) efficacy in JIA associated uveitis. <h3>Methods</h3> Among 17 patients with JIA and eye involvement included in the study, 9 children had oligo-articular JIA, 7 children – polyarticular, 1 patient had systemic disease. Study group included 13 girls and 4 boys. Mean age was 7,10 ± 2,16 years, age of disease onset was 3,70±3,05years; mean disease duration before ABA administration was 6,40±3,21. Disease onset with initial joint damage was observed in 10 children, with eye involvement- in 7 children. Prior to ABA administration all children received immunosuppressive drugs: 12 children (70,58%) methotrexate (MTX) 10–15mg/m<sup>2</sup> of body surface per week, 2 children (11,8%) received Sandimunne Neoral as monotherapy and with methotrexate combination – 3 patients (17,6%), 2 children received oral corticosteroids (CS), 17 children (100%) received topical treatment of uveitis. Number of active joints was 8,7±2,6, mean ESR was 20, 0±10,32mm/h, CRP 1,18±1,05mg/dl (ref. &lt;0,8mg/dl). RF positive was detected in 2 children, negative - in 15 children, ANA positive in 14 children (82,35%) with 1:160- 1:180 rate. VAS physician was 73, 4±15, 0, VAS patient/parent was 68, 7±16, 2. Mean functional disability in patients before ABA administration was 1, 03 ±0, 48. All 17 patients had active uveitis at the moment of ABA administration. 9 (53%) patients had bilateral ocular involvement, 8 patients (47%) - unilateral. <h3>Results</h3> After 6 months of ABA therapy mean ESR decreased from 20, 0±12, 32 mm/h to 17.2±4,28mm/h, CRP – from 1, 18±1, 05 mg/dl to 1,05±0,75mg/dl. ACRpedi-30 was achieved in 10 from 17 (58,82) % patients, ACRpedi-50- in 4 patients (23,52%), ACRpedi -70- in 3 children (17,64%). Uveitis remission was achieved in 22% eyes; 46% showed a significant reduction in inflammatory activity, 32% had no significant dynamic. After 12 months of ABA therapy number of active joints decreased from 8, 7±2, 6 to 5, 63± 1, 4. Mean ESR decreased from 20, 0±12, 32 mm/h to 10,0±4,6mm/h, CRP –0±0,31mg/dl, VAS physician decreased from 73, 4±15,0 to 42,4±13,5, VAS patient/parent decreased from 68, 7±16, 2 to 50,0 ± 14,0. ACRpedi-50 was achieved in 13 patients (76,4%), ACRpedi-80 - in 2 children (11,76%). Regarding uveitis 21% eyes had uveitis remission; 36% – sub active process. Flares were observed in 43% eyes. <h3>Conclusions</h3> Abatacept treatment during 12 months period was effective in JIA associated uveitis with 82% ANA positivity without previous biologics therapy. <h3>Disclosure of Interest</h3> None declared
Whole Genome Sequence Analysis of Primary Myelofibrosis.
Authors: Jason D. Merker, Krishna Roskin, Dana Ng, Cuiping Pan, Dianna G. Fisk, Carol D. Jones, Linda Gojenola, Michael J. Clark, Bing Zhang, Michael Cherry, Michael Snyder, Scott D. Boyd, James L. Zehnder, Andrew Z. Fire, Jason Gotlib
Journal: Blood (2012)
T-Cell Replete Haploidentical Transplantation Using Post-Transplant Cyclophosphamide Results in Equivalent Non-Relapse Mortality and Disease-Free Survival Compared to Transplantation From HLA-Identical Sibling and Matched Unrelated Donors: A Stratified Cox Model Analysis of Two Hundred and Sixty Contemporaneous Allogeneic Transplants From a Single Center
Authors: Asad Bashey, Xu Zhang, Connie A. Sizemore, Karen Manion, Stacey Brown, H. Kent Holland, Scott R. Solomon, Lawrence E. Morris
Journal: Blood (2011)
A Single-Center Study To Evaluate the Safety and Efficacy of Intravenous/Oral Fludarabine in Untreated Gastric MALT Lymphoma. Impact of t(11;18)(q21;q21) in Molecular Response Rates.
Authors: Antonio Salar, Beatriz Bellosillo, Agustín Seoane, Luz Martinez, Ana Ferrer, Sergio Serrano, Carlos Besses
Journal: Blood (2007)
FRI0501 Investigation of Joint Hypermobility in Individuals with Indirect Hyperbilirubinemia and Acrocyanosis
Authors: M. Cinar, M. Cakar, K. Ozturk, S. Yilmaz, A. Dinc
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Hypermobility represents the excessive mobility of the joints. Joint hypermobility syndrome (JHS) is defined as the musculoskeletal symptoms in individuals with hypermobility in the absence of any systemic rheumatic disease, and the incidence in the general population is about 0.5%. A biochemical or structural disorder affecting collagen synthesis is assumed as an underlying mechanism in hypermobility syndrome. In animal studies, bilirubin has been shown to reduce fibrosis induced by bleomycin. In these studies, it is suggested that bilirubin leads to hypermobility by affecting the structure or function of collagen. In addition, our observation in clinical practice is that hypermobility and acrocyanosis is more common in patients with indirect hyperbilirubinemia. <h3>Objectives</h3> This study aimed to evaluate the frequency of hypermobility and acrocyanosis in patients with indirect hyperbilirubinemia. <h3>Methods</h3> The study recruited 120 consecutive patients with indirect hyperbilirubinemia examined in gastroenterology outpatient clinics of a university hospital and 107 healthy individuals as a control group with normal bilirubin levels. Patients were examined for the presence of hypermobility and acrocyanosis. Hypermobility was determined by using Beighton scoring (Score, 0–9). To conclude whether the JHS was present, Brighton criteria were used. Acrocyanosis was identified by history and compatible physical examination. <h3>Results</h3> The mean age of the patients and the control group enrolled in the study were 33.4 ± 12.9 and 36.2 ± 11.2 years, respectively (p=0.09). 100 of the patients (83%) and 78 (73%) of the control group of were males (p=0.075). The average indirect bilirubin levels of the study and control groups were 1.44 ± 0.66 mg/dL and 0.37 ± 0.18 mg/dl, respectively. By Beighton scoring, 23 patients (19.2%) in the study group and 3 (2.8%) individuals in the control group had joint hypermobility. The difference between groups was statistically significant (p&lt;0.001). 4 patients in the study group and 1 individual in the control group had JHS, and the difference was not statistically significant (p=0.220). In 35 (29.2%) of study patients and 12 (11.2%) individuals in the control group had acrocyanosis. The difference between groups was statistically significant (p=0.001). Joint hypermobility did not have any significant relationship with the presence of acrocyanosis (p=0.441). <h3>Conclusions</h3> According to the results of our study, joint hypermobility and acrocyanosis is more frequent in patients with indirect hyperbilirubinemia compared to controls. This finding suggests that bilirubin has a role in both diseased. It should be determined whether they share a common or difference pathogenic pathway. <h3>References</h3> Beighton P, Solomon L, Soskolne CL. Articular mobility in an African population. Ann Rheum Dis. 1973;32(5):413–8. <h3>Disclosure of Interest</h3> None declared
Fears raised over plan to scale back GP and A&E care in east London
Authors: Adrian O’Dowd
Journal: BMJ (2016)

Experts have raised concerns at plans for east London that could mean replacing GPs with other professionals and scaling back accident and emergency activity in hospitals to focus such care in the community.

The independent think tank the Centre for Health and the Public Interest has analysed plans outlined in a multiagency document called Transforming Services Together ,1 which seems to have been included in the wider northeast London sustainability and transformation plan (STP).2 The STPs are the new ways for areas across England to come up with proposals to improve health and save money.

The think tank said, in its report,3 that although the full STP proposals for northeast London contained few specific details, the detail given in the Transforming Services Together document seemed to form part …
FRI0267 Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-Related Interstitial Lung Disease: Scleroderma Lung Study II
Authors: D. Khanna, M. Roth, P. Clements, D. Furst, C.-H. Tseng, R. Elashoff, E. Volkmann, S. Kafaja, J. Goldin, D. Tashkin
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Progressive Interstitial lung disease (ILD) occurs in ∼ 40% of scleroderma (SSc) patients and is the leading cause of death. Oral CYC for 1 year in SSc-ILD led to modest but significant improvements in lung function and dyspnea vs. placebo (Tashkin, NEJM, 2006) but the benefits were lost over the ensuing year and drug therapy was not extended due to the known toxicity profile of CYC. (Tashkin AJRCCM 2007). Preliminary data from uncontrolled clinical studies suggest that MMF may be an effective and safer immunosuppressive therapy than CYC for SSc-ILD. <h3>Objectives</h3> A randomized controlled trial was performed to determine the efficacy, safety and tolerability of mycophenolate mofetil (MMF) administered for two years compared with CYC administered for one year followed by matching placebo for SSc-ILD. <h3>Methods</h3> 142 patients with pulmonary function and high-resolution computed tomography (HRCT) defined SSc-ILD were randomized at 14 centers to receive MMF or CYC. The primary endpoint, change in forced vital capacity (FVC%&gt;predicted) over 24 months, was assessed using a joint longitudinal model (Elashoff, Statist Med 2006). <h3>Results</h3> 126 patients (63 MMF; 63 CYC) had ≥3 months of outcome data and were included in the primary analysis. A greater number of patients on CYC than on MMF prematurely withdrew from (32 vs 20) and failed treatment (2 vs 0), and the time to stopping treatment was significantly shorter in the CYC arm (p=0.019). At 24-months, the adjusted FVC%&gt;predicted had improved by 2.17 in the MMF arm (95% CI, 0.53–3.84; p&lt;0.01) and 2.86 in the CYC arm (95% confidence interval 1.19–4.58; p&lt;0.001) with no significant between-treatment difference (p=0.24). Significant within- (but not between-) treatment improvements in skin score, dyspnea and whole-lung HRCT scores were also observed. Leukopenia and thrombocytopenia occurred more often with CYC (p&lt;0.05). Sixteen deaths occurred (11 CYC; 5 MMF) with most due to underlying disease. <h3>Conclusions</h3> In this first RCT comparing MMF with CYC in SSc-ILD, both agents appeared to have comparable efficacy but MMF was better tolerated with significantly fewer premature withdrawals from treatment and fewer adverse events. These findings support the increasingly common clinical practice of prescribing MMF for this disease. <h3>Acknowledgement</h3> Funded by the National Heart, Lung, and Blood Institute, National Institutes of Health; ClinicalTrials.gov number NCT00883129. <h3>Disclosure of Interest</h3> None declared